期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 178, 期 13, 页码 2569-2594出版社
WILEY
DOI: 10.1111/bph.15456
关键词
ADHD; anxiety; depression; N‐ acetylcysteine; obsessive– compulsive disorder; posttraumatic stress disorder; schizophrenia
资金
- Maj Institute of Pharmacology Polish Academy of Sciences
N-acetylcysteine (NAC) is a well-known mucolytic agent that has shown beneficial effects on different psychiatric disorders. It exerts its effects through regulating neurotransmitters, oxidative balance, and inflammatory mediators. While preclinical studies have shown positive results, further research is needed to establish the clinical efficacy of NAC for psychiatric disorders.
N-acetylcysteine (NAC) is a well-known and safe mucolytic agent, also used in patients with paracetamol overdose. In addition to these effects, recent preclinical and clinical studies have shown that NAC exerts beneficial effects on different psychiatric disorders. Many potential mechanisms have been proposed to underlie the therapeutic effects of NAC, including the regulation of several neurotransmitters, oxidative homeostasis, and inflammatory mediators. In this paper, we summarize the current knowledge on the ability of NAC to ameliorate symptoms and neuropathologies related to different psychiatric disorders, including attention deficit hyperactivity disorder, anxiety, bipolar disorder, depression, obsessive-compulsive disorder, obsessive-compulsive-related disorder, posttraumatic stress disorder, and schizophrenia. Although preclinical studies have shown a positive effect of NAC on animal models of psychiatric disorders, the clinical efficacy of NAC is not fully established. NAC remains a strong candidate for adjunct treatment for many psychiatric disorders, but additional preclinical and clinical studies are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据